Table 2. Anti-HAV and anti-HBs seropositivity/seroprotection rates and GMTs (ATP analysis).
| Results | 6 mo after 1st dose of HAV/HBV vaccine* | 1 mo after 2nd dose of HAV/HBV vaccine | ||
|---|---|---|---|---|
| Group Co-adm n = 207 (95%CI) |
Group Sep n = 199 (95%CI) |
Group Co-adm n = 207 (95%CI) |
Group Sep n = 199 (95%CI) |
|
| Anti-HAV + | 100% (98.3–100) |
100% (98.2–100) |
100% (98.2–100) |
100% (98.2–100) |
| Anti-HAV ≥ 20IU/L | 67.1% (60.3–73.4) |
72.9% (66.1–78.8) |
100% (98.2–100) |
99.5% (97.2–99.9) |
| Anti-HAV GMTs |
30.5 IU/L (27.1–34.3) |
38.2 IU/L (33.4–43.6) |
2962 IU/L (2598–3379) |
2129 IU/L (1808–2507) |
| Anti-HBs + | 56.5% (49.5–63.4) |
72.9% (66.1–78.9) |
98.1% (95.1–99.5) |
99.0% (96.4–99.9) |
| Anti-HBs ≥ 10IU/L | 43.5% (36.6–50.5) |
59.3% (52.1–66.2) |
97.6% (94.5–99.2) |
97.5% (94.2–99.2) |
| Anti-HBs GMTs |
7.3 IU/L (5.8–9.2) |
12.5 IU/L (9.8–15.8) |
1701 IU/L (1339–2159) |
2005 IU/L (1585–2536) |
*
HAV/HBV vaccine – Twinrix-Junior®